Working… Menu

The Effectiveness of Pain Management Using the ARCHIMEDES® Constant-Flow Infusion Pump System for Intrathecal Delivery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00196053
Recruitment Status : Completed
First Posted : September 20, 2005
Last Update Posted : May 2, 2012
Information provided by:
Codman & Shurtleff

Brief Summary:
The purpose of this observational registry is to collect a continuum of meaningful clinical data on the ARCHIMEDES implantable pump in pain management

Condition or disease Intervention/treatment Phase
Chronic Pain Device: Archimedes Constant Flow Implantable Pump Phase 4

Detailed Description:

Pain management has been a long-standing challenge to the medical community, specifically for the treatment of chronic pain. Chronic Pain is defined by the American Chronic Pain Association as "pain that continues a month or more beyond the usual recovery period for an illness or injury or pain that goes on over months or years as a result of a chronic condition." Chronic pain affects the patient's quality of life, work performance and attendance, mental health, social interactions and overall activities of daily living.

Implantable pumps were used for cancer and non-cancer patients, who had pain, which was resistant to conventional therapy. Intrathecal morphine administration is now accepted as a safe and effective method of controlling or reducing pain and its impact on the sufferer.

The Codman ARCHIMEDES Implantable Constant-Flow Infusion Pump is CE marked, and has been commercially available in Europe for intrathecal delivery of morphine and baclofen since August 1997. ARCHIMEDES is intended for the treatment of chronic intractable (cancer or non-cancer) pain, which requires chronic intrathecal infusion of preservative-free morphine sulfate.

This is a European, multicenter, prospective, single arm, observational registry conducted on a total of 150 Subjects at up to 10 centers in Europe.

Subjects will be followed at 3, 6, 9, and 12 months post Archimedes implant to assess their pain management and quality of life.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 55 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Observational Registry: The Effectiveness of Pain Management Using the ARCHIMEDES® Implantable Constant-Flow Infusion Pump System for Intrathecal Delivery
Study Start Date : March 2005
Actual Primary Completion Date : August 2007
Actual Study Completion Date : August 2007

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Pain management measured by the visual analog pain scale [ Time Frame: Quarterly for 1 year post-implant ]
  2. Pain management measured by quality of life score (SF-36) [ Time Frame: Quarterly for 1 year post-implant ]

Secondary Outcome Measures :
  1. Device-related adverse events over the duration of the study [ Time Frame: End of trial ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The Subject has been suffering from chronic (benign and/or malignant) intractable pain for at least 2 or more months duration (pending national laws) with a pre-implant value equal or more than 7 on the Visual Analog Pain Scale.
  • The subject does not tolerate oral pain medication at the required therapeutic dose to treat his/her pain.
  • The Subject has a minimum reasonable life expectancy of at least 6 months.
  • The Subject has given written Informed Consent prior to enrollment into this study.
  • The body size of the Subject is sufficient to accept the pump bulk and weight, per the Principal Investigator's discretion.
  • The Subject is willing to participate in this registry for 1 year post implant and is willing to comply with the investigational plan requirements.
  • It is the Principal Investigator's judgment, based on the knowledge of the Subject, and Subject's condition, as well as the features of the implantable system that the Subject is an appropriate candidate for pain management utilizing an implantable pump for continuously delivering preservative-free morphine sulfate via an intrathecal route.

Exclusion Criteria:

  • The Subject has a skin condition (i.e., scleroderma, psoriasis, rash, or open wound) at the site chosen for implantation that would compromise the integrity or access to the injection port.
  • The Subject has previously enrolled in or participated in an investigational drug or device trial within the preceding 4 weeks.
  • The Subject has any known contraindication to preservative-free morphine sulfate.
  • The Subject has a suspected or documented allergy to preservative-free morphine sulfate or related drugs.
  • The Subject has a suspected or documented allergy to the materials of the infusion pump or catheter(s) (for example, silicone).
  • The Subject has a history of drug and/or alcohol abuse per Principal Investigator discretion.
  • The Subject is a female who is pregnant or lactating.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00196053

Layout table for location information
Laon, France, 02000
Bamberg, Germany, 81677
Freiburg, Germany, 79106
Konstanz, Germany, 78461
Meppen, Germany, 49704
Tutzing, Germany, 82327
United Kingdom
Middlesbrough, United Kingdom, TS4 3BW
Plymoth, United Kingdom, PL6 8DH
Sponsors and Collaborators
Codman & Shurtleff
Layout table for investigator information
Study Director: Michael Ward, DVM Unaffilliated
Layout table for additonal information
Responsible Party: Michael Ward, Worldwide Director, Clinical Research, Codman & Shurtleff Identifier: NCT00196053    
Other Study ID Numbers: DDS-EU04-001
EU Pain Registry
First Posted: September 20, 2005    Key Record Dates
Last Update Posted: May 2, 2012
Last Verified: April 2012
Keywords provided by Codman & Shurtleff:
Intrathecal pain management
constant flow pump
Additional relevant MeSH terms:
Layout table for MeSH terms
Chronic Pain
Neurologic Manifestations